Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 30, 2025 08:00 ET | Source: Posit Science

The 2025 Brain Health Breakthrough of the Year

SAN FRANCISCO, Dec. 30, 2025 (GLOBE NEWSWIRE) -- A broadly syndicated article has put the INHANCE Study at the top of the list of brain health breakthroughs for older adults in 2025. With the...
December 23, 2025 08:01 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease

ROCHESTER, N.Y., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) by...
December 22, 2025 08:00 ET | Source: Sinaptica Therapeutics

Sinaptica Therapeutics Completes Scientific Advisory Board, Bringing Together Leading Voices Across Patients, Science, Medicine, and Commercial Strategy

CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Sinaptica Therapeutics, a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat...
December 16, 2025 08:00 ET | Source: Annovis Bio Inc.

Annovis to Host Corporate Update Webinar on January 28, 2026

Annovis will host corporate update webinar on January 28, 2026
December 08, 2025 19:43 ET | Source: RetinalGeniX Technologies, Inc.

RetinalGenix Technologies Agrees To Hire M. Cory Zwerling as CFO, Interim COO

RetinalGenix signs agreement to hire M. Cory Zwerling as its chief financial officer and interim chief operating officer, effective January 1, 2026
November 24, 2025 08:00 ET | Source: Annovis Bio Inc.

Annovis Announces Two Presentations at the CTAD 2025 Conference

Annovis attends CTAD 2025 with two presentations highlighting new biomarker data in Alzheimer's and Parkinson's diseases.
November 18, 2025 08:00 ET | Source: Annovis Bio Inc.

Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study

MALVERN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for...
November 12, 2025 08:00 ET | Source: Annovis Bio Inc.

Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for...
November 11, 2025 09:00 ET | Source: Gnome Sciences

Gnome Sciences Announces Cancer Drug Shows Promise in Stopping Progression of ALS

Gnome Sciences Discovers Cancer Drug Shows Promise in Stopping Progression of ALS. BCL2 inhibitors such as venetoclax may treat neurodegenerative diseases
November 10, 2025 08:00 ET | Source: Posit Science

Cognitive Training Found Most Effective Lifestyle Intervention to Prevent Cognitive Decline

SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- A comprehensive systematic review of lifestyle interventions to prevent cognitive decline, which published in the prestigious British medical journal...